Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axogen Inc (NQ: AXGN )

5.840 +0.170 (+3.00%)
Streaming Delayed Price Updated: 2:34 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 166,812
Open 5.690
Bid (Size) 5.810 (4)
Ask (Size) 5.840 (3)
Prev. Close 5.670
Today's Range 5.655 - 6.000
52wk Range 3.450 - 10.83
Shares Outstanding 41,397,053
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
AXGN Stock Earnings: Axogen Beats EPS, Misses Revenue for Q1 2024
AXGN stock results show that Axogen beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Axogen, Inc Reports First Quarter 2024 Financial Results
From Axogen, Inc.
Via GlobeNewswire

Performance

YTD
-15.48%
-15.48%
1 Month
-26.26%
-26.26%
3 Month
-38.91%
-38.91%
6 Month
+48.60%
+48.60%
1 Year
-39.54%
-39.54%

More News

Read More
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
From Axogen, Inc.
Via GlobeNewswire
Axogen Earnings Preview
Via Benzinga
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
From Axogen, Inc.
Via GlobeNewswire
Earnings Scheduled For March 5, 2024
Via Benzinga
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
From Axogen, Inc.
Via GlobeNewswire
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
From Axogen, Inc.
Via GlobeNewswire
Crude Oil Rises Over 2%; Constellation Brands Posts Downbeat Sales
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Greenbrier Posts Upbeat Earnings, Joins Kura Sushi USA, AxoGen And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
From Axogen, Inc.
Via GlobeNewswire
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
From Axogen, Inc.
Via GlobeNewswire
Axogen Announces Promotions on Research and Development Team
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors
From Axogen, Inc.
Via GlobeNewswire
Axogen Announces Transition of Finance Team Leadership
From Axogen, Inc.
Via GlobeNewswire
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. Reports 2023 Third Quarter Financial Results
From Axogen, Inc.
Via GlobeNewswire
Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023
From Axogen, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.